131I Radioconjugated Antibodies for the Locoregional Radioimmunotherapy of High-grade Malignant Glioma: Phase I and II Study

REFERENCES

• Loeffler JS, Shrieve DC, Coleman CN. Chemoradiation and adjuvant chemotherapy: why does so much therapy yield so little improvement in survival? Int .1- Radiat Oncol Biol Phyis 1995; 33: 531–3.
   Google Scholar
• Jeremic B, Antunovic V, Djuric L, Stojanovic M, Shibamoto Y. Influence of the extent of surgery and tumor location on treatment outcome of patients with glioblastoma multiforme treated with combined modality approach. J Neurooncol 1994; 21: 177–85.
   Google Scholar
• Jubelirer SJ. A review of the treatment and survival rates of 138 patients with glioblastoma multiforme. W V Med J 1996; 92: 186–90.
   PubMedGoogle Scholar
• Westlin JE, Snook D, Nilsson S, et al. Intravenous and intratumoural therapy of patients with malignant gliomas with 'Yttrium labeled monoclonal antibody MUC 2-63. In: Epenetos A, ed. Monoclonal antibodies: applications in clini-cal oncology. London, New York: Chapman and Hall Medica, 1992: 17–25.
   Google Scholar
• Papanastassiou V, Pizer BL, Coakham HB, et al. Treatment of recurrent and cystic malignant glioma by a single intracav-itary injection of 1-131 monoclonal antibody: feasibility, phar-macokinetics and dosimetry. Br J Cancer 1993; 67: 144–51.
   PubMed Web of Science ®Google Scholar
• Riva P, Arista A, Sturiale C, et al. Treatment of intracranial human glioblastoma by direct intratumoral administration of 131I-labelled anti-tenascin monoclonal antibody. Int J Cancer 1992; 51: 7–13.
   PubMed Web of Science ®Google Scholar
• Leprini A, Querze G, Zardi L. Tenascin isoforms: possible targets for diagnosis and therapy of cancer and mechanisms regulating their expression. Perspect Dev Neurobiol 1994; 2: 117–23.
   Google Scholar
• Lee YS, Bullard D, Humprey PA, et al. Treatment of in-tracranial human glioma xenografts with 131I-labeled antite-nascin monoclonal antibody 8106. Cancer Res 1988; 48: 2904–10.
   PubMed Web of Science ®Google Scholar
• Zalutsky MR, Moseley RP, Coakham HB, Coleman RE, Bigner DD. Pharmacokinetics and tumor localization of 1311. labeled anti-tenascin monoclonal antibody 8106 in patients with gliomas and other intracranial malignancies. Cancer Res 1989; 49: 2807–13.
   Google Scholar
• Arista A, Sturiale C, Riva P, et al. Intralesional administra-tion of 1-131 labelled monoclonal antibodies in the treatment of malignant gliomas. Acta Neurochir 1995; 135: 159–62.
   PubMed Web of Science ®Google Scholar
• P. Riva, A. Arista, C. Sturiale, et al. Intralesional therapy of glioma In: New antibody technology and the emergence of useful cancer therapy. Begent R, Hamblin A, eds. London: The Royal Society of Medicine Press, 1995: 23–6.
   Google Scholar
• Kaplan El, Maier P. Non parametric estimation from incom-plete observations. J Am Stat Assoc 1958; 53: 457–81.
   Web of Science ®Google Scholar
• Riva P, Arista A, Tison V, et al. Intralesional radioim-munotherapy of malignant glioma: an effective treatment in recurrent tumors. Cancer 1994; 73 (Suppl): 1076–82.
   Google Scholar
• Muto MG, Finkler NJ, Kassis Al, Lepisto EM, Knapp RC. Human anti-murine antibody responses in ovarian cancer patients undergoing radioimmunotherapy with the murine monoclonal antibody 0C-125. Gynecol Oncol 1990; 38: 244–8.
   Google Scholar
• Sturiale C, Arista A, Lazzari S, et al. Intralesional radioim-munotherapy of malignant gliomas: clinical experiences with recurrent and primary tumours. Tumor Targeting 1995; 1: 163–76.
   Google Scholar
• P. Riva, A. Arista, C. Sturiale, et al. Radioimmunotherapy of CNS malignant gliomas by direct intralesional injection of specific 1–131 radiolabeled monoclonal antibodies. In: Cancer therapy with radiolabeled antibodies. Goldenberg DM, ed. Boca Raton, Ann Arbor, London, Tokyo: CRC Press, 1995: 203–16.
   Google Scholar
• Riva P, Arista A, Sturiale C, et al. Glioblastoma therapy by direct intralesional administration of 1–131 radioiodine labeled antitenascin antibodies. Cell Biophysics 1994; 24/25: 37–43.
   Google Scholar
• Baum RP, Niesen A, Hertel A, et al. Activating anti-idio-thypic human anti-mouse antibodies for immunotherapy of ovarian carcinoma. Cancer 1994;73 (Suppl): 1121–5.
   Google Scholar
• Brady LW, Miyamoto C, Woo DV, et al. Malignant astrocy-tomas treated with iodine-125 labeled monoclonal antibody 425 against epidermal growth factor receptor: a phase II trial. Int J Radiat Oncol Biol Phys 1992; 22: 225–30.
   PubMed Web of Science ®Google Scholar
• Hopkins K, Chandler C, Bullimore J, et al. A pilot study of the treatment of patients with recurrent malignant gliomas with intratumoral yttrium-90 radioimmunoconjugates. Radio-ther Oncol 1995; 34: 121–31.
   PubMed Web of Science ®Google Scholar
• Riva P, Arista A, Franceschi G, et al. Local treatment of malignant gliomas by direct infusion of specific monoclonal antibodies labelled with 1311. Comparison of the results ob-tained in recurrent and newly diagnosed tumours. Cancer Res 1995; 55: 5952s–6s.
   Google Scholar
• Riva PG. Franceschi G, Arista A, et al. Local application of radiolabeled MAbs for the treatment of high grade malignant gliomas: a six year clinical experience. Cancer 1997; 80 (Suppl): 2733–42.
   Google Scholar